Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
#1PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
tirzepatide · Heart failure with preserved ejection fraction · Obesity · glucose-dependent insulinotropic polypeptide receptor agonist · GLP-1 receptor agonist · Worsening heart failure events · Cardiovascular mortality · KCCQ Clinical Summary Score · KCCQ Clinical Summary Score · health status · quality of life · subcutaneous administration · weight loss · Body mass index · Left ventricular ejection fraction · gastrointestinal adverse events · Time-to-event analysis · SUMMIT trial
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459